RBC Capital maintains Gilead Sciences stock rating on Yeztugo concerns By Investing.com

RBC Capital reiterated a Sector Perform rating on Gilead Sciences with a $123 price target, below the current $139.77 share price, and said Yeztugo persistence appears likely at or below 70%. The firm sees a likely first-quarter launch beat but warns that variability in re-dosing and shifting capture rates could pressure long-term peak sales expectations. Overall, the note is cautious rather than bearish, with the stock already up 37% over the past year.

Analysis

The setup is less about near-term revenue surprise and more about how quickly the market is willing to pay for durability. If persistence is already soft this early in the launch curve, the implied lifetime value per patient is likely being overstated, which matters because the bullish thesis depends on a long runway of repeat dosing and continued payer enthusiasm. That creates a classic biopharma multiple-risk asymmetry: the first few quarters can look good on launch math while the terminal value gets quietly compressed.

The more interesting second-order effect is competitive. If adoption is being driven by initial switchers rather than sticky new users, then the broader PrEP market may be more elastic than bulls assumed, which favors incumbents with lower friction and entrenched prescribing habits. That also raises the bar for any next-wave prevention assets: pricing power becomes harder to sustain if real-world persistence is closer to a 70% ceiling than a near-perfect re-dose curve.

For TEM, the incremental read-through is modestly positive because broader Gilead R&D digitization spending validates demand for AI-enabled workflow tools in pharma R&D, but this is more of a budget-line tailwind than a material fundamental inflection. ACLX is effectively neutral here; the better takeaway is that Gilead’s acquisition appetite signals management is still willing to pay for pipeline optionality, which can support sentiment around external innovation partners and M&A comps across oncology/immune-oncology. Near term, the stock is vulnerable into earnings if the market decides launch momentum is already peaking before persistence data can improve.

Key Decisions for Investors

• Fade strength in GILD into earnings over the next 1-2 weeks via a short-dated call spread or outright short against a biotech basket; risk/reward favors downside because the market is paying for a long-duration adoption curve that may be too optimistic.
• Pair trade: long TEM / short GILD for 1-3 months. The thesis is that AI workflow vendors can capture recurring pharma spend regardless of a single asset’s persistence, while GILD faces valuation compression if launch-quality concerns deepen.
• For more conservative exposure, buy GILD puts or put spreads expiring just after earnings to express event risk without carrying full delta. Best setup is if implied volatility stays elevated but not extreme.
• Do not add to ACLX on this headline alone; use it only as an M&A optionality vehicle. The better entry would be on any post-earnings pullback or sector-wide weakness, not on this news flow.